Molidustat

• Description :

  Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia[1][2].

• Product Name Alternative :

  BAY 85-3934

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H360, H372

• Target :

  HIF/HIF Prolyl-Hydroxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Molidustat.html

• Purity :

  99.70

• Solubility :

  DMSO : 5 mg/mL (ultrasonic)

• Smiles :

  O=C1C(N2N=NC=C2)=CNN1C3=NC=NC(N4CCOCC4)=C3

• Molecular Formula :

  C13H14N8O2

• Molecular Weight :

  314.30

• Precautions :

  H302, H360, H372

• References & Citations :

  [1]Flamme I, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9 (11) :e111838.|[2]Yamamoto H, et al. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Am J Nephrol. 2021;52 (10-11) :884-893.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [1154028-82-6]